Interferon for Hepatitis C: Where it has been and where it is Going

Abstract

ImmunotherapyVol. 5, No. 7 EditorialInterferon for hepatitis C: where it has been and where it is goingRonald L KoretzRonald L KoretzDepartment of Medicine, Olive View – UCLA Medical Center, 14445 Olive View Drive, Sylmar, CA 91340, USA. Search for more papers by this authorEmail the corresponding author at rkoretz@msn.comPublished Online:5 Jul 2013https://doi.org/10.2217/imt.13.55AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: hepatitis Cinterferonsurrogate end pointtreatmentReferences1 Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leucocyte interferon on hepatitis B infection in patients with chronic active hepatitis. N. Engl. J. Med.295,517–522 (1976).Crossref, Medline, CAS, Google Scholar2 Davis GL, Balart LA, Schiff ER et al.; Hepatitis Interventional Therapy Group.Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med.321(22),1501–1506 (1989).Crossref, Medline, CAS, Google Scholar3 Innes HA, Hutchinson SJ, Allen S et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology54,1547–1558 (2011).Crossref, Medline, Google Scholar4 Management of hepatitis C. NIH Consensus Statement15(3),1–41 (1997).Google Scholar5 Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis: a National Heart, Lung, and Blood Institute Collaborative study. Hepatology33,455–463 (2001).Crossref, Medline, CAS, Google Scholar6 Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med.340,1228–1233 (1999).Crossref, Medline, CAS, Google Scholar7 Seeff LB, Miller RN, Rabin CS et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann. Intern. Med.132,105–111 (1999).Crossref, Google Scholar8 Koretz RL. Chronic hepatitis: more words from the literature and sponsor. In: Current Hepatology. Gitnick G (Ed.). Mosby Year Book, Inc., St. Louis, MO, USA 17,51–96 (1997).Google Scholar9 Ikeda K, Kumada H, Saitoh S et al. A randomized controlled trial of interferon-α in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus. J. Hepatol.28,910–911 (1998).Crossref, Medline, CAS, Google Scholar10 Mura D, Deliperi R, Fastame L et al. Interferon therapy of HCV cirrhosis reduces the incidence of HCC, and decompensation, and significantly improves survival: a 5 year comparative trial. Hepatology29,A1251 (1999).Google Scholar11 Valla DC, Chevallier M, Marcellin P et al. Treatment of hepatitis C virus-related cirrhosis: a randomized controlled trial of interferon α-2b versus no treatment. Hepatology29,1870–1875 (1999).Crossref, Medline, CAS, Google Scholar12 Fartoux L, Degos F, Trepo C et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin. Gastroenterol. Hepatol.5,502–507 (2007).Crossref, Medline, CAS, Google Scholar13 Bernardinello E, Cavalletto L, Chemello et al. Long-term clinical outcome after β-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology46,3216–3222 (1999).Medline, CAS, Google Scholar14 Pockros P, Jeffers L, Afdhal N et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ 1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology45,569–578 (2007).Crossref, Medline, CAS, Google Scholar15 Tanwar S, Wright M, Foster GR et al. Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. Eur. J. Gastroenerol. Hepatol.24,543–550 (2012).Crossref, Medline, CAS, Google Scholar16 Bruix J, Poynard T, Colombo M et al. Maintenance therapy with peginterferon α-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology140,1990–1999 (2011).Crossref, Medline, CAS, Google Scholar17 Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med.359,2429–2441 (2008).Crossref, Medline, CAS, Google Scholar18 Di Bisceglie AM, Stoddard AM, Dienstag JL et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology53,1100–1108 (2011).Crossref, Medline, CAS, Google Scholar19 Koretz RL, Pleguezuelo M, Arvaniti V et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst. Rev.1,CD003617 (2013).Medline, Google Scholar20 Poordad F, Lawitz E, Kowdley KV et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N. Engl. J. Med.368,45–53 (2013).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByAn injectable thermosensitive hydrogel/nanomicelles composite for local chemo-immunotherapy in mouse model of melanoma11 May 2022 | Journal of Biomaterials Applications, Vol. 37, No. 3 Vol. 5, No. 7 Follow us on social media for the latest updates Metrics Downloaded 43 times History Published online 5 July 2013 Published in print July 2013 Information© Future Medicine LtdKeywordshepatitis Cinterferonsurrogate end pointtreatmentFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download